Comparing medications for NMOSD
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD, a rare autoimmune condition affecting the nerves.
- You tested positive for the AQP4 antibody with a special blood test.
- You are 18 years or older.
- You are able to attend study visits and follow the procedures.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have active hepatitis B, hepatitis C, or untreated tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if ravulizumab can lower certain nerve damage markers in people with AQP4-positive neuromyelitis optica. It may help understand how well the treatment works.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This study follows people with NMOSD (a rare autoimmune disease that can cause vision loss and paralysis) to learn more about the condition. It may help doctors better understand and treat NMOSD in the future.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This study tests whether a new experimental medicine called CC-97540 is safe and well-tolerated in patients with a rare neurological disease called neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody marker (anti-AQP4). The trial involves a procedure that removes and reprocesses some of your immune cells.
Hear when a new NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.